Top Story
December 3, 2019
A combination of atezolizumab and bevacizumab conferred statistically significant and clinically meaningful improvements in PFS and OS compared with sorafenib among patients with unresectable hepatocellular carcinoma, according to results of the randomized phase 3 IMbrave150 study presented at European Society for Medical Oncology Asia Congress.
“This is the first study in 11 years to show an improvement in survival with a new first-line treatment option compared to sorafenib, which had been the standard of care throughout this time,” Ann-Lii Cheng, MD, PhD, director of National Taiwan University Cancer Center, said in a press release. “Atezolizumab plus bevacizumab has the potential to be a practice-changing treatment option in hepatocellular carcinoma.”